K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · ALNY
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | ALNYLAM PHARMACEUTICALS, INC. | $430K | Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing Issues relating to supply chain tariffs Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act. |
| 2026-04-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | SPLITOAK STRATEGIES LLC | $60K | RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness |
| 2026-04-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TODD STRATEGY GROUP | $60K | Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act. |
| 2026-04-17 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TIBER CREEK GROUP | $60K | Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing. |
| 2026-04-17 | ALNY | ALNYLAM PHARMACEUTICALS INC. | LMH STRATEGIC SOLUTIONS | $50K | General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization. |
| 2026-04-16 | ALNY | ALNYLAM PHARMACEUTICALS INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. |
| 2026-01-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | ALNYLAM PHARMACEUTICALS, INC. | $390K | Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing. Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act Issues relating to supply chain tariffs |
| 2026-01-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TIBER CREEK GROUP | $60K | Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing. |
| 2026-01-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | SPLITOAK STRATEGIES LLC | $60K | RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946/S. 1862, ORPHAN Cures Act; P.L. 119-21; U.S. Competitiveness |
| 2026-01-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TODD STRATEGY GROUP | $60K | Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. |
| 2026-01-18 | ALNY | ALNYLAM PHARMACEUTICALS INC. | CAPITOL COUNSEL LLC | $30K | Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. |
| 2026-01-12 | ALNY | ALNYLAM PHARMACEUTICALS INC. | LMH STRATEGIC SOLUTIONS | $70K | General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization. |
| 2025-10-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | ALNYLAM PHARMACEUTICALS, INC. | $390K | Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act Issues relating to supply chain tariffs Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94) |
| 2025-10-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | LMH STRATEGIC SOLUTIONS | $70K | General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. Pediatric Review Reauthorization. |
| 2025-10-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | SPLITOAK STRATEGIES LLC | $60K | RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946/S. 1862, ORPHAN Cures Act; P.L. 119-21 |
| 2025-10-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TODD STRATEGY GROUP | $60K | Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. |
| 2025-10-20 | ALNY | ALNYLAM PHARMACEUTICALS | THE MCMANUS GROUP | $20K | Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022 |
| 2025-10-19 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TIBER CREEK GROUP | $60K | Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing. |
| 2025-10-15 | ALNY | ALNYLAM PHARMACEUTICALS INC. | CAPITOL COUNSEL LLC | $30K | Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. |
| 2025-10-11 | ALNY | ALNYLAM PHARMACEUTICALS INC. | SPLITOAK STRATEGIES LLC | $60K | RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526) |
| 2025-07-21 | ALNY | ALNYLAM PHARMACEUTICALS | THE MCMANUS GROUP | $60K | Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022 |
| 2025-07-21 | ALNY | ALNYLAM PHARMACEUTICALS INC. | SPLITOAK STRATEGIES LLC | $60K | RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946/S. 1862, ORPHAN Cures Act; P.L. 119-21 |
| 2025-07-20 | ALNY | ALNYLAM PHARMACEUTICALS INC. | ALNYLAM PHARMACEUTICALS, INC. | $390K | Issues related to the implementation of the Inflation Reduction Act. Issues relating to supply chain tariffs |
| 2025-07-19 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TODD STRATEGY GROUP | $60K | Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. |
| 2025-07-19 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TIBER CREEK GROUP | $60K | Issues related to H.R. 946/S.1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act. |
| 2025-07-17 | ALNY | ALNYLAM PHARMACEUTICALS INC. | CAPITOL COUNSEL LLC | $30K | Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. |
| 2025-07-15 | ALNY | ALNYLAM PHARMACEUTICALS INC. | LMH STRATEGIC SOLUTIONS | $30K | General Medicare and Medicaid Issues. H.R.1672 - Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862 - ORPHAN Cures Act. PRV. |
| 2025-04-21 | ALNY | ALNYLAM PHARMACEUTICALS INC. | ALNYLAM PHARMACEUTICALS, INC. | $440K | Issues related to Medicare coverage of home infusion; issues related to the implementation of the Inflation Reduction Act. Issues related to veterans healthcare. |
| 2025-04-21 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TODD STRATEGY GROUP | $60K | Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Home infusion. |
| 2025-04-21 | ALNY | ALNYLAM PHARMACEUTICALS INC. | SPLITOAK STRATEGIES LLC | $60K | RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946, ORPHAN Cures Act |
| 2025-04-21 | ALNY | ALNYLAM PHARMACEUTICALS | THE MCMANUS GROUP | $60K | Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022 |
| 2025-04-18 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TIBER CREEK GROUP | $60K | Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to home infusion under Medicare FFS; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act. |
| 2025-04-18 | ALNY | ALNYLAM PHARMACEUTICALS INC. | LMH STRATEGIC SOLUTIONS | $30K | Home Infusions Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. |
| 2025-04-17 | ALNY | ALNYLAM PHARMACEUTICALS INC. | CAPITOL COUNSEL LLC | $20K | Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. |
| 2025-03-09 | ALNY | ALNYLAM PHARMACEUTICALS INC. | LMH STRATEGIC SOLUTIONS | $0 | Home Infusions Issues. |
| 2025-03-07 | ALNY | ALNYLAM PHARMACEUTICALS INC. | CAPITOL COUNSEL LLC | $0 | Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. |
| 2025-01-21 | ALNY | ALNYLAM PHARMACEUTICALS INC. | ALNYLAM PHARMACEUTICALS, INC. | $500K | Issues related to Medicare coverage of home infusion; issues related to the implementation of the Inflation Reduction Act Issues related to veterans healthcare |
| 2025-01-21 | ALNY | ALNYLAM PHARMACEUTICALS | THE MCMANUS GROUP | $60K | Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act |
| 2025-01-21 | ALNY | ALNYLAM PHARMACEUTICALS INC. | SPLITOAK STRATEGIES LLC | $60K | RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appropriate home infusion (H.R. 5397, Joe Fiandra Access to Home Infusion Act; AINS to H.R. 8816; AINS to H.R. 5526); H.R.10545 - American Relief Act, 2025 |
| 2025-01-21 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TODD STRATEGY GROUP | $60K | Medicare and Medicaid Issues. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home infusion. |
| 2025-01-19 | ALNY | ALNYLAM PHARMACEUTICALS INC. | TIBER CREEK GROUP | $60K | Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to home infusion under Medicare FFS; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act. |